Table 3 Economic outcomes for full and subpopulations in short and long-term time horizons
Mean outcome | TF3+  | TF3+ EM only | TF3+ CM only |
|---|---|---|---|
5-year horizon | |||
 QALYs, eptinezumab | 2.95 | 3.17 | 2.70 |
 QALYs, BSC | 2.71 | 2.99 | 2.37 |
 Discounted QALYs, eptinezumab | 2.72 | 2.92 | 2.48 |
 Discounted QALYs, BSC | 2.49 | 2.75 | 2.17 |
 Cost of eptinezumab acquisition | £7,497 | £5,998 | £9,267 |
 Cost of eptinezumab administration | £967 | £773 | £1,195 |
 Cost of disease management, eptinezumab | £2,399 | £2,212 | £2,621 |
 Cost of disease management, BSC | £2,548 | £2,356 | £2,775 |
 Cost of rescue therapy, eptinezumab | £780 | £517 | £1,091 |
 Cost of rescue therapy, BSC | £957 | £632 | £1,340 |
 Cost of work impairment, eptinezumab | £33,650 | £27,425 | £41,000 |
 Cost of work impairment, BSC | £47,257 | £40,332 | £55,433 |
 Total undiscounted cost, eptinezumab | £45,294 | £36,925 | £55,173 |
 Total undiscounted cost, BSC | £50,762 | £43,320 | £59,548 |
 Total discounted cost, eptinezumab | £41,804 | £34,078 | £50,925 |
 Total discounted cost, BSC | £46,698 | £39,829 | £54,809 |
 Cost-saving versus BSC | £4,894 | £5,751 | £3,883 |
 ICER, £ | Dominant in the SE quadrant | Dominant in the SE quadrant | Dominant in the SE quadrant |
 Net monetary benefit @ £20,000, £ | £9,515 | £8,938 | £10,010 |
Lifetime horizon | |||
 QALYs, eptinezumab | 22.30 | 22.95 | 21.53 |
 QALYs, BSC | 21.72 | 22.54 | 20.74 |
 Discounted QALYs, eptinezumab | 11.91 | 12.38 | 11.35 |
 Discounted QALYs, BSC | 11.46 | 12.06 | 10.75 |
 Cost of eptinezumab acquisition | £18,463 | £14,025 | £23,702 |
 Cost of eptinezumab administration | £2,380 | £1,808 | £3,056 |
 Cost of disease management, eptinezumab | £15,006 | £14,428 | £15,688 |
 Cost of disease management, BSC | £15,406 | £14,823 | £16,087 |
 Cost of rescue therapy, eptinezumab | £3,500 | £2,666 | £4,485 |
 Cost of rescue therapy, BSC | £3,936 | £2,957 | £5,091 |
 Cost of work impairment, eptinezumab | £179,749 | £162,457 | £200,163 |
 Cost of work impairment, BSC | £258,749 | £238,088 | £282,824 |
 Total undiscounted cost, eptinezumab | £219,098 | £195,384 | £247,093 |
 Total undiscounted cost, BSC | £277,943 | £255,869 | £304,003 |
 Total discounted cost, eptinezumab | £133,127 | £115,610 | £153,806 |
 Total discounted cost, BSC | £163,225 | £147,121 | £182,236 |
 ICER, £ | Dominant in the SE quadrant | Dominant in the SE quadrant | Dominant in the SE quadrant |
 Net monetary benefit @ £20,000 | £39,056 | £37,892 | £40,429 |